

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-66. (canceled)

67. (currently amended) A method for modulating angiogenesis comprising introducing a zinc finger protein into an animal having a genome comprising a target site within a vascular endothelial growth factor (VEGF) gene, whereby the zinc finger protein binds to the target site and thereby modulates angiogenesis in the animal.

68. (currently amended) The method according to claim 67, wherein the zinc finger protein binds to a target site specified in Table 3 (SEQ ID NOS: 1-29 and 244) or Table 4 (SEQ ID NOS: 117-119).

69. (currently amended) The method according to claim 68, wherein positions -1 to +6 in each of three zinc fingers are occupied by first (SEQ ID NOS: 30-58), second (SEQ ID NOS: 69-87, 112, and 245-252) and third segments (SEQ ID NOS: 42, 68 and 88-116) of seven contiguous amino acids as specified in a row of Table 3.

70. (currently amended) The method according to claim 68, wherein the zinc finger protein comprises six zinc fingers, and positions -1 to +6 in each of the six zinc fingers are occupied by [[a]] first (SEQ ID NOS: 117-119), second (SEQ ID NOS: 120-122), third (SEQ ID NOS: 123-125), fourth (SEQ ID NOS: 126-128), fifth (SEQ ID NOS: 129-131) and sixth (SEQ ID NOS: 132-134) segment segments of seven contiguous amino acids as specified in a row of Table 4.

71. (original) The method according to claim 67, wherein the target site is present in a plurality of VEGF genes, whereby the zinc finger protein binds to the target site in the plurality of genes, thereby modulating expression of the plurality of VEGF genes.

72-74. (canceled)

75. (currently amended) A method of treating ischemia, comprising administering a zinc finger protein that binds to a target site ~~specified in Table 3 or 4~~ within a VEGF gene into an animal having ischemia, wherein the animal has a genome comprising a VEGF gene comprising the target site and the zinc finger protein binds to the target site, and wherein the zinc finger protein is administered in an amount effective to treat ischemia.

76. (canceled)

77. (original) The method according to claim 76, wherein the zinc finger protein comprises at least three fingers of the C2H2 class of zinc fingers.

78-94. (canceled)

95. (original) A method for treating a wound comprising introducing a zinc finger protein into an animal having a genome comprising a target site within a VEGF gene, whereby the zinc finger protein binds to the target site, such binding accelerating healing of the wound.

96. (New) The method according to claim 95, wherein the zinc finger protein binds to a target site specified in Table 3 (SEQ ID NOS: 1-29 and 244) or Table 4 (SEQ ID NOS: 117-119).

97. (new) The method according to claim 96, wherein positions -1 to +6 in each of three zinc fingers are occupied by first (SEQ ID NOS: 30-58), second (SEQ ID NOS: 69-87, 112, and 245-252) and third segments (SEQ ID NOS: 42, 68 and 88-116) of seven contiguous amino acids as specified in a row of Table 3.

98. (new) The method according to claim 96, wherein the zinc finger protein comprises six zinc fingers, and positions -1 to +6 in each of the six zinc fingers are occupied by [[a]] first (SEQ ID NOS: 117-119), second (SEQ ID NOS: 120-122), third (SEQ ID NOS: 123-125), fourth (SEQ ID NOS: 126-128), fifth (SEQ ID NOS: 129-131) and sixth (SEQ ID NOS: 132-134) segments of seven contiguous amino acids as specified in a row of Table 4.

99. (new) The method of claim 95, wherein the zinc finger protein is applied topically.

100. (new) The method according to claim 75, wherein the zinc finger protein binds to a target site specified in Table 3 (SEQ ID NOS: 1-29 and 244) or Table 4 (SEQ ID NOS: 117-119).

101. (new) The method according to claim 100, wherein positions -1 to +6 in each of three zinc fingers are occupied by first (SEQ ID NOS: 30-58), second (SEQ ID NOS: 69-87, 112, and 245-252) and third segments (SEQ ID NOS: 42, 68 and 88-116) of seven contiguous amino acids as specified in a row of Table 3.

102. (new) The method according to claim 100, wherein the zinc finger protein comprises six zinc fingers, and positions -1 to +6 in each of the six zinc fingers are occupied by [[a]] first (SEQ ID NOS: 117-119), second (SEQ ID NOS: 120-122), third (SEQ ID NOS: 123-125), fourth (SEQ ID NOS: 126-128), fifth (SEQ ID NOS: 129-131) and sixth (SEQ ID NOS: 132-134) segments of seven contiguous amino acids as specified in a row of Table 4.

103. (new) The method of claim 75, wherein the zinc finger protein is applied to a specific tissue of the animal.